

HPMS E-Mail

Date: March 18, 2024

Subject: Forthcoming VBID Prescription Drug Event (PDE) Reporting Guidance for Contract Year (CY) 2024

The Centers for Medicare & Medicaid Services (CMS) has received technical questions from Medicare Advantage Organizations (MAOs) and other interested parties about the treatment of the Value-Based Insurance Design (VBID) Model flexibility to provide targeted reductions in Part D cost sharing, specifically scenarios where a participating plan has waived the full Low-Income Subsidy (LIS) copay for all drugs for LIS category 1 and 2 beneficiaries in Calendar Year (CY) 2024. CMS plans to address these concerns through forthcoming guidance and specific Prescription Drug Event (PDE) examples.